Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 17, 2021 09:06 ET | Source: First Wave BioPharma, Inc.

First Wave BioPharma Announces Adjournment of Annual Meeting

BOCA RATON, Fla., Dec. 17, 2021 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
December 09, 2021 07:00 ET | Source: First Wave BioPharma, Inc.

First Wave BioPharma Names Brian Feagan, M.D., to Scientific Advisory Board

BOCA RATON, Fla., Dec. 09, 2021 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
November 30, 2021 07:00 ET | Source: First Wave BioPharma, Inc.

First Wave BioPharma Announces Independent Data Monitoring Committee Provides Positive Interim Safety Assessment for Part 2 COVID-19 RESERVOIR Clinical Trial of Niclosamide for the Treatment of Gastrointestinal Infections

BOCA RATON, Fla., Nov. 30, 2021 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
November 16, 2021 07:00 ET | Source: First Wave BioPharma, Inc.

First Wave BioPharma Announces Restructuring of Merger Consideration Payment Terms With Former Shareholders of First Wave Bio

BOCA RATON, Fla., Nov. 16, 2021 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI), (“First Wave BioPharma,” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
October 14, 2021 09:00 ET | Source: First Wave BioPharma, Inc.

First Wave BioPharma Announces Dosing of First Patient in Phase 2b Clinical Trial Evaluating Topical Niclosamide in Patients with Ulcerative Proctitis and Ulcerative Proctosigmoiditis

BOCA RATON, Fla., Oct. 14, 2021 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
October 12, 2021 08:30 ET | Source: First Wave BioPharma, Inc.

First Wave BioPharma Announces Two Additions to Scientific Advisory Board

BOCA RATON, Fla., Oct. 12, 2021 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
September 28, 2021 08:00 ET | Source: First Wave BioPharma, Inc.

First Wave BioPharma Begins Patient Screening for Phase 2b Clinical Trial Evaluating Niclosamide in Patients with Ulcerative Proctitis and Ulcerative Proctosigmoiditis

Preliminary data from prior Phase 1a/2a trial indicated safety of topical formulation of FW-UP and suggested possible favorable efficacy First Proof of Principle for Treatment of Inflammatory...
September 21, 2021 12:47 ET | Source: AzurRx BioPharma, Inc.

AzurRx BioPharma to Change Corporate Name to First Wave BioPharma Today

BOCA RATON, Fla., Sept. 21, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX) (“First Wave” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development...
September 14, 2021 07:30 ET | Source: AzurRx BioPharma, Inc.

AzurRx BioPharma CEO Issues Letter to Shareholders Regarding Recent Acquisition of First Wave Bio and Creation of First Wave BioPharma

BOCA RATON, Fla., Sept. 14, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the...
September 13, 2021 06:00 ET | Source: AzurRx BioPharma, Inc.

AzurRx BioPharma Announces Acquisition of First Wave Bio and its Proprietary Niclosamide Formulations Targeting Multi-Billion Dollar Inflammatory Bowel Disease Indications

AzurRx BioPharma to be renamed “First Wave BioPharma” and trade under new NASDAQ ticker symbol, “FWBI” Three IBD clinical indications, including ulcerative colitis and Crohn’s disease, added to GI...